LETTER TO THE EDITOR
Effect of tissue factor pathway inhibitor on thrombin generation assay
First published: 15 November 2021
CONFLICT OF INTEREST
Among the authors, J. Douxfils is CEO and founder of QUALIblood s.a., a contract research organization manufacturing the DP-Filter, is co-inventor of the DP-Filter (patent application number: PCT/ET2019/ 052903), and reports personal fees from Daiichi-Sankyo, Mithra Pharmaceuticals, Stago, Roche, and Roche Diagnostics outside the submitted work. F. Mullier reports institutional fees from Stago, Werfen, Nodia, Roche Sysmex, and Bayer. He also reports speaker fees from Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb-Pfizer, Stago, Sysmex, and Aspen all outside the submitted work. A. Carlo is an employee of the Stago Company. The other authors have no conflicts of interest to disclose.
Open Research
DATA AVAILABILITY STATEMENT
Data available on request from the authors
